Safety, efficacy, and pharmacokinetics of delgocitinib ointment in infants with atopic dermatitis: A phase 3, open-label, and long-term study

Nakagawa, Hidemi; Igarashi, Atsuyuki; Saeki, Hidehisa; Kabashima, Kenji; Tamaki, Tomomi; Kaino, Hironobu; Miwa, Yasushi

doi:10.1016/j.alit.2023.04.003

Cited by 7 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a meta-analysis by Tsai et al, while topical delgocitinib had a higher rate of achieving an EASI-75 response, other topical agents like ruxolitinib or tofacitinib had demonstrated a better response with regard to IGA and the pruritus-NRS response [186]. A phase III, open-label, and long-term study demonstrated that delgocitinib in both formulations (0.025% and 0.5%) applied twice a day on skin lesions are well tolerated and effective for up to 52 weeks when applied to Japanese infants with AD [187].…”

Section: Jak Inhibitors Topical Jak Inhibitorsmentioning

confidence: 99%

Challenges and Future Trends in Atopic Dermatitis

Gatmaitan,

Lee

2023

IJMS

View full text Add to dashboard Cite

Atopic dermatitis represents a complex and multidimensional interaction that represents potential fields of preventive and therapeutic management. In addition to the treatment armamentarium available for atopic dermatitis, novel drugs targeting significant molecular pathways in atopic dermatitis biologics and small molecules are also being developed given the condition’s complex pathophysiology. While most of the patients are expecting better efficacy and long-term control, the response to these drugs would still depend on numerous factors such as complex genotype, diverse environmental triggers and microbiome-derived signals, and, most importantly, dynamic immune responses. This review article highlights the challenges and the recently developed pharmacological agents in atopic dermatitis based on the molecular pathogenesis of this condition, creating a specific therapeutic approach toward a more personalized medicine.

show abstract

Section: Jak Inhibitors Topical Jak Inhibitorsmentioning

confidence: 99%